Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Raltegravir potassium
Drug ID BADD_D01906
Description Raltegravir is an antiretroviral drug produced by Merck & Co., used to treat HIV infection. It received approval by the U.S. Food and Drug Administration (FDA) on 12 October 2007, the first of a new class of HIV drugs, the integrase inhibitors, to receive such approval.
Indications and Usage For the treatment of HIV-1 infection in conjunction with other antiretrovirals.
Marketing Status Prescription
ATC Code J05AJ01
DrugBank ID DB06817
KEGG ID D07133
MeSH ID D000068898
PubChem ID 23668479
TTD Drug ID D0I1FQ
NDC Product Code 65015-841; 67651-0276; 50473-0001; 67317-0031; 70600-028; 67317-0001; 67651-0274; 62331-055; 65977-0129; 67651-0275
Synonyms Raltegravir Potassium | Potassium, Raltegravir | Raltegravir | MK 0518 | 0518, MK | MK0518 | MK-0518 | Isentress
Chemical Information
Molecular Formula C20H20FKN6O5
CAS Registry Number 871038-72-1
SMILES CC1=NN=C(O1)C(=O)NC(C)(C)C2=NC(=C(C(=O)N2C)[O-])C(=O)NCC3=CC=C(C=C3)F.[K+]
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Influenza22.07.02.001; 11.05.03.001--Not Available
Insomnia17.15.03.002; 19.02.01.002--
International normalised ratio increased13.01.02.008--
Iron deficiency anaemia14.13.02.001; 01.03.01.002--Not Available
Kaposi's sarcoma16.33.02.001; 11.05.17.001--Not Available
Lethargy19.04.04.004; 17.02.04.003; 08.01.01.008--
Lipase increased13.05.01.003--
Lipoatrophy23.07.01.001; 14.08.04.006--
Liver disorder09.01.08.001--Not Available
Low density lipoprotein increased13.12.01.005--Not Available
Lymph node pain01.09.01.007--
Lymphadenopathy01.09.01.002--Not Available
Lymphoma16.20.01.001; 01.12.01.001--Not Available
Malaise08.01.01.003--
Memory impairment17.03.02.003; 19.20.01.003--
Menopausal symptoms21.02.02.002--Not Available
Mental disability26.01.01.001--Not Available
Mental impairment19.21.02.003; 17.03.03.002--Not Available
Middle insomnia19.02.01.003; 17.15.03.003--Not Available
Migraine17.14.02.001; 24.03.05.003--Not Available
Molluscum contagiosum11.05.12.001; 23.09.03.006--Not Available
Mood swings19.04.03.001--Not Available
Musculoskeletal pain15.03.04.007--
Myalgia15.05.02.001--
Myocardial infarction24.04.04.009; 02.02.02.007--
Myopathy15.05.05.001--Not Available
Nasal congestion22.04.04.001--
Nasopharyngitis22.07.03.002; 11.01.13.002--Not Available
Nausea07.01.07.001--
Neck pain15.03.04.009--
The 5th Page    First    Pre   5 6 7 8 9    Next   Last    Total 9 Pages